<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma - Peinemann, F - 2015 | Cochrane Library</title> <meta content="Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma - Peinemann, F - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010774.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma - Peinemann, F - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010774.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010774.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma" name="citation_title"/> <meta content="Frank Peinemann" name="citation_author"/> <meta content="University of Cologne" name="citation_author_institution"/> <meta content="pubmedprjournal@gmail.com" name="citation_author_email"/> <meta content="Doreen A Kahangire" name="citation_author"/> <meta content="University of Birmingham" name="citation_author_institution"/> <meta content="Elvira C van Dalen" name="citation_author"/> <meta content="Emma Children's Hospital/Academic Medical Center" name="citation_author_institution"/> <meta content="Frank Berthold" name="citation_author"/> <meta content="Children's Hospital, University of Cologne" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD010774.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/05/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010774.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010774.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010774.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antineoplastic Combined Chemotherapy Protocols [administration &amp; dosage, adverse effects, *therapeutic use]; Carboplatin [administration &amp; dosage, adverse effects]; Cisplatin [administration &amp; dosage, adverse effects]; Cyclophosphamide [administration &amp; dosage, adverse effects]; Drug Administration Schedule; Etoposide [administration &amp; dosage, adverse effects]; Induction Chemotherapy [adverse effects, *methods]; Neuroblastoma [*drug therapy]; Randomized Controlled Trials as Topic; Vincristine [administration &amp; dosage, adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010774.pub2&amp;doi=10.1002/14651858.CD010774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="tIsQXAzh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010774\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010774\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010774.pub2",title:"Rapid COJEC versus standard induction therapies for high\\u2010risk neuroblastoma",firstPublishedDate:"May 19, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Childhood Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010774.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010774.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010774.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010774.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010774.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010774.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010774.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010774.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010774.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010774.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2489 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010774.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-sec-0083"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-sec-0023"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-sec-0024"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/appendices#CD010774-sec-0088"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/table_n/CD010774StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/table_n/CD010774StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/information#CD010774-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Frank Peinemann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/information#CD010774-cr-0003">Doreen A Kahangire</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/information#CD010774-cr-0004">Elvira C van Dalen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010774.pub2/information#CD010774-cr-0005">Frank Berthold</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/information/en#CD010774-sec-0094">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 May 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010774.pub2">https://doi.org/10.1002/14651858.CD010774.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010774-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010774-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010774-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010774-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010774-abs-0001" lang="en"> <section id="CD010774-sec-0001"> <h3 class="title" id="CD010774-sec-0001">Background</h3> <p>Neuroblastoma is a rare malignant disease and mainly affects infants and very young children. The tumors mainly develop in the adrenal medullary tissue and an abdominal mass is the most common presentation. The high‐risk group is characterized by metastasis and other characteristics that increase the risk for an adverse outcome. In the rapid COJEC induction schedule, higher single doses of selected drugs than standard induction schedules are administered over a substantially shorter treatment period, with shorter intervals between cycles. Shorter intervals and higher doses increase the dose intensity of chemotherapy and might improve survival. </p> </section> <section id="CD010774-sec-0002"> <h3 class="title" id="CD010774-sec-0002">Objectives</h3> <p>The aim of this study was to evaluate the efficacy and adverse events of the rapid COJEC induction schedule as compared to standard induction schedules in patients with high‐risk neuroblastoma (as defined by the International Neuroblastoma Risk Group (INRG) classification system). Outcomes of interest were complete response, early toxicity and treatment‐related mortality as primary endpoints and overall survival, progression‐ and event‐free survival, late non‐hematological toxicity, and health‐related quality of life as secondary endpoints. </p> </section> <section id="CD010774-sec-0003"> <h3 class="title" id="CD010774-sec-0003">Search methods</h3> <p>We searched the electronic databases CENTRAL (2014, Issue 11), MEDLINE (PubMed), and EMBASE (Ovid) for articles from inception to 11 November 2014. Further searches included trial registries, conference proceedings, and reference lists of recent reviews and relevant articles. We did not apply limits on publication year or languages. </p> </section> <section id="CD010774-sec-0004"> <h3 class="title" id="CD010774-sec-0004">Selection criteria</h3> <p>Randomized controlled trials evaluating the rapid COJEC induction schedule for high‐risk neuroblastoma patients compared to standard induction schedules. </p> </section> <section id="CD010774-sec-0005"> <h3 class="title" id="CD010774-sec-0005">Data collection and analysis</h3> <p>Two review authors performed study selection, abstracted data on study and patient characteristics, and assessed risk of bias independently. We resolved differences by discussion or by appeal to a third review author. We performed analyses according to the guidelines of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. We used the five GRADE considerations, study limitations, consistency of effect, imprecision, indirectness, and publication bias, to judge the quality of the evidence. We downgraded for risk of bias and imprecision </p> </section> <section id="CD010774-sec-0006"> <h3 class="title" id="CD010774-sec-0006">Main results</h3> <p>We identified one randomized controlled trial (CCLG‐ENSG‐5) that included 262 patients with high‐risk neuroblastoma who were randomized to receive either rapid COJEC (N = 130) or standard OPEC/COJEC (N = 132) induction chemotherapy. We graded the evidence as low quality; we downgraded for risk of bias and imprecision. </p> <p>There was no clear evidence of a difference between the treatment groups in complete response (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.71 to 1.38), treatment‐related mortality (RR 1.21, 95% CI 0.33 to 4.39), overall survival (hazard ratio (HR) 0.83, 95% CI 0.63 to 1.10), and event‐free survival (HR 0.86, 95% CI 0.65 to 1.13). We calculated the HRs using the complete follow‐up period of the trial. </p> <p>Febrile neutropenia (two or more episodes), proven fungal infections, septicemia (one or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate &lt; 80 ml/min per body surface area of 1.73 m<sup>2</sup>), neurological toxicity (grade 3 or 4), and ototoxicity (Brock grade 2 to 4) were addressed as early toxicities (during pre‐operative chemotherapy). For febrile neutropenia, septicemia, and renal toxicity, a statistically significant difference in favor of the standard treatment arm was identified; for all other early toxicities no clear evidence of a difference between treatment groups was identified. With regard to late non‐hematological toxicities (median follow‐up 12.7 years; range 6.9 to 16.5 years), the study provided data on any complication, renal toxicity (glomerular filtration rate &lt; 80 ml/min per body surface area of 1.73m<sup>2</sup>), ototoxicity (Brock grade 1 to 4), endocrine complications, neurocognitive complications (i.e. behavioral, speech, or learning difficulties), and second malignancies. For endocrine complications and neurocognitive complications, a statistically significant difference in favor of the rapid COJEC arm was found; for all other late non‐hematological toxicities no clear evidence of a difference between treatment groups was identified. </p> <p>Data on progression‐free survival and health‐related quality of life were not reported.</p> </section> <section id="CD010774-sec-0007"> <h3 class="title" id="CD010774-sec-0007">Authors' conclusions</h3> <p>We identified one randomized controlled trial that evaluated rapid COJEC versus standard induction therapy in patients with high‐risk neuroblastoma. No clear evidence of a difference in complete response, treatment‐related mortality, overall survival, and event‐free survival between the treatment alternatives was found. This could be the result of low power or too short a follow‐up period. Results of both early and late toxicities were ambiguous. Information on progression‐free survival and health‐related quality of life were not available. This trial was performed in the 1990s. Since then, many changes in, for example, treatment and risk classification have occurred. Therefore, based on the currently available evidence, we are uncertain about the effects of rapid COJEC and standard induction therapy in patients with high‐risk neuroblastoma. More research is needed for a definitive conclusion. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010774-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010774-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010774-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010774-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010774-abs-0004">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010774-abs-0003" lang="en"> <h3>Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma</h3> <p>High‐risk neuroblastoma is a rare malignant disease and mainly affects infants and very young children. The tumors mainly develop in the core part (medulla) of the adrenal gland. The adrenal gland is located on top of the kidneys. A tumor increasing in size would primarily expected to appear in the belly. High‐risk means patients having one or several clinical symptoms or signs, such as metastasis or specific genetic features, which are known to increase the risk for an adverse outcome. The assignment to a high‐risk group is defined by the International Neuroblastoma Risk Group (INRG) classification system. In the rapid COJEC induction schedule, higher single doses of selected drugs than standard induction schedules are administered over a substantially shorter treatment period, with shorter intervals between cycles. Shorter intervals and higher doses increase the dose intensity of chemotherapy and might improve survival. </p> <p>We identified one randomized controlled trial with 262 patients. We excluded other study designs as they give less reliable results. However, randomized studies are difficult to perform in children with neuroblastoma and other evidence might be available. In the identified randomized study, patients with high‐risk neuroblastoma were randomized to receive either rapid COJEC or standard OPEC/OJEC induction chemotherapy. Complete response, treatment‐related mortality, overall survival, and event‐free survival were not different between the two treatment alternatives. Results of both early and late toxicities were not clear cut, for example, some early toxicities were in favor of the standard arm and some late non‐hematological toxicities were in favor of the rapid COJEC arm. For other toxicities there was no evidence of a difference between the treatment arms. Data on progression‐free survival and health‐related quality of life were not reported. Not all biases could be ruled out in this study. Before definitive conclusions can be made more research is needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010774-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010774-sec-0083"></div> <h3 class="title" id="CD010774-sec-0084">Implications for practice</h3> <section id="CD010774-sec-0084"> <p>We identified one randomized controlled trial (RCT) that evaluated rapid COJEC as an induction therapy versus standard induction therapy in patients with high‐risk neuroblastoma. The difference in complete response and treatment‐related toxicity, as well as overall survival and event‐free survival, between the treatment alternatives was not statistically significantly different. This could be the result of low power or too short a follow‐up period. Results of both early and late toxicities were ambiguous. Information on progression‐free survival and health‐related quality of life were not available. Also, this trial was performed between 1990 and 1999; since then many changes in, for example, treatment and risk classification have occurred. Therefore, based on the currently available evidence, we are uncertain about the effects of rapid COJEC and standard induction therapy in patients with high‐risk neuroblastoma. More research is needed for a definitive conclusion. </p> </section> <h3 class="title" id="CD010774-sec-0085">Implications for research</h3> <section id="CD010774-sec-0085"> <p>Future trials on the use of rapid COJEC as an induction therapy for children with high‐risk neuroblastoma should be RCTs focusing on survival, early and late adverse events, and quality of life. RCTs should be performed in homogeneous study populations (for example, stage of disease) and have a long‐term follow‐up. The number of included patients should be sufficient to obtain the power needed for the results to be reliable. Different risk groups, using the most recent definitions, should be taken into account. For example, potential subgroups of patients may benefit from rapid COJEC. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010774-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010774-sec-0015"></div> <div class="table" id="CD010774-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Rapid COJEC compared to standard induction therapies for high‐risk neuroblastoma</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Rapid COJEC compared to standard induction therapies for high‐risk neuroblastoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with high‐risk neuroblastoma<br/> <b>Settings:</b> pediatric oncology departments<br/> <b>Intervention:</b> rapid COJEC<br/> <b>Comparison:</b> standard induction therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Standard induction therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Rapid COJEC </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>456 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>451 per 1000</b> <br/> (323 to 629) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> <br/> (0.71 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of follow‐up was not reported regarding the 262 randomized patients; median follow‐up of 62 alive patients was 12.5 years (range 0 to 16.5 years) </p> <p>This was an available data analysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Early toxicities (during preoperative chemotherapy): febrile neutropenia (2 or more episodes), proven fungal infections, septicemia (1 or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate &lt; 80 ml/min per body surface area of 1.73 m<sup>2</sup>), neurological toxicity (grade 3 or 4), ototoxicity (Brock grade 2 to 4)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of follow‐up was not reported regarding the 262 randomized patients; median follow‐up of 62 alive patients was 12.5 years (range 0 to 16.5 years) </p> <p>Febrile neutropenia: there was a significant difference in favor of the standard induction therapy arm (RR 1.23, 95% CI 1.10 to 1.36) </p> <p>Proven fungal infections: no significant difference between treatment groups (RR 2.50, 95% CI 0.23 to 27.18) </p> <p>Septicemia: there was a significant difference in favor of the standard induction therapy arm (RR 1.61, 95% CI 1.14 to 2.27) </p> <p>Gastrointestinal toxicity: no significant difference between treatment groups (RR 1.41, 95% CI 0.96 to 2.08) </p> <p>Renal toxicity: there was a significant difference in favor of the standard induction therapy arm (RR 2.19, 95% CI 1.39 to 3.44) </p> <p>Neurological toxicity: no significant difference between treatment groups (RR 3.07, 95% CI 0.63 to 14.93) </p> <p>Ototoxicity: no significant difference between treatment groups (RR 1.04, 95% CI 0.27 to 4.01) </p> <p>These were all available data analyses</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐related mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> <br/> (11 to 153) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> <br/> (0.33 to 4.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of follow‐up was not reported regarding the 262 randomized patients; median follow‐up of 62 alive patients was 12.5 years (range 0 to 16.5 years) </p> <p>This was an available data analysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>811 per 1000</b><sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>749 per 1000</b> <br/> (649 to 840) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.83</b> <br/> (0.63 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of follow‐up was not reported regarding the 262 randomized patients; median follow‐up of 62 alive patients was 12.5 years (range 0 to 16.5 years) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information on this outcome was provided</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Event‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>818 per 1000</b><sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>769 per 1000</b> <br/> (670 to 854) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.86</b> <br/> (0.65 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of follow‐up was not reported regarding the 262 randomized patients; median follow‐up of 62 alive patients was 12.5 years (range 0 to 16.5 years) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Late non‐hematological toxicities: any complication, renal toxicity (Glomerular Filtration Rate &lt; 80 ml/min per body surface area of 1.73 m<sup>2</sup>), ototoxicity (Brock grade 1 to 4), endocrine complications (see table of included studies for included disorders), neurocognitive complications (i.e. behavioral, speech, or learning difficulties), and second malignancies</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of follow‐up was not reported regarding the 69 patients eligible for late toxicities (i.e. at least 5‐year survivors); median follow‐up for the 57 analyzed long‐term survivors was 12.7 years (6.9 to 16.5 years) </p> <p>Any complication: no significant difference between treatment groups (RR 0.95, 95% CI 0.71 to 1.26) </p> <p>Renal toxicity: no significant difference between treatment groups (RR 0.32, 95% CI 0.09 to 1.22) </p> <p>Ototoxicity: no significant difference between treatment groups (RR 1.35, 95% CI 0.73 to 2.50) </p> <p>Endocrine complications: there was a significant difference in favor of the rapid COJEC arm (RR 0.42, 95% CI 0.18 to 0.96) </p> <p>Neurocognitive complications: there was a significant difference in favor of the rapid COJEC arm (RR 0.27, 95% CI 0.09 to 0.79) </p> <p>Second malignancies: no significant difference between treatment groups (Fischer's exact P value = 0.55) </p> <p>These were all available data analyses</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR:</b> hazard ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The assumed risk is based on the prevalence in the control group of the included study.<br/> <sup>2</sup>The presence of selection bias, performance bias, detection bias, and other bias was unclear; there was a high risk of attrition bias.<br/> <sup>3</sup>The total number of events was fewer than 300 (the threshold rule‐of‐thumb value stated in the GRADEpro software).<br/> <sup>4</sup>The assumed risk is based on the number of events in the control group at the final time point of the survival curve presented in the included study.<br/> <sup>5</sup>The presence of selection bias, performance bias, and other bias was unclear; there was a high risk of attrition bias.<br/> <sup>6</sup>As yet no threshold rule‐of‐thumb value for the minimal number of events for time‐to‐event data is included in the GRADEpro software; however, since this is a small study and the 95% confidence interval include values both favoring the intervention and the control treatment, we downgraded for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010774-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010774-sec-0016"></div> <section id="CD010774-sec-0017"> <h3 class="title" id="CD010774-sec-0017">Description of the condition</h3> <p>Neuroblastoma is a rare malignant disease that affects mainly infants and very young children (<a href="./references#CD010774-bbs2-0037" title="Genetic and Rare Diseases Information Center (GARD), The Office of Rare Diseases Research (ORDR). Neuroblastoma. http://rarediseases.info.nih.gov/GARD/Condition/7185/Neuroblastoma.aspx (accessed 8 July 2013). ">GARD 2013</a>). Tumors develop in the sympathetic nervous system (e.g. in the adrenal medullary tissue or paraspinal ganglia) and may be localized or metastatic at diagnosis (<a href="./references#CD010774-bbs2-0033" title="ColeKA , MarisJM . New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clinical Cancer Research2012;18(9):2423‐8. ">Cole 2012</a>). The median age at diagnosis is 17 months and the incidence rate of neuroblastoma is age‐dependent, with an incidence rate of 64 per million children in the first year of life, falling to 29 per million children in the second year of life (<a href="./references#CD010774-bbs2-0038" title="GoodmanMT , GurneyJG , SmithMA , OlshanAF . SEER Pediatric Monograph. Sympathetic Nervous System Tumors. http://seer.cancer.gov/publications/childhood/sympathetic.pdf (accessed 8 July 2013). ">Goodman 2012</a>). The incidence rate in adults is less than one per million per year, but adults have a considerably worse prognosis (<a href="./references#CD010774-bbs2-0036" title="EsiashviliN , GoodmanM , WardK , MarcusRBJr , JohnstonePA . Neuroblastoma in adults: incidence and survival analysis based on SEER data. Pediatric Blood and Cancer2007;49(1):41‐6. ">Esiashvili 2007</a>). The International Neuroblastoma Risk Group (INRG) classification system, proposed by <a href="./references#CD010774-bbs2-0032" title="CohnSL , PearsonAD , LondonWB , MonclairT , AmbrosPF , BrodeurGM , et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of Clinical Oncology2009;27(2):289‐97. ">Cohn 2009</a>, is shown in <a href="#CD010774-tbl-0002">Table 1</a>. The authors of <a href="./references#CD010774-bbs2-0032" title="CohnSL , PearsonAD , LondonWB , MonclairT , AmbrosPF , BrodeurGM , et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of Clinical Oncology2009;27(2):289‐97. ">Cohn 2009</a> estimated the event‐free survival for each of the four risk groups and tested the clinical importance of 13 potential prognostic factors. The Children's Oncology Group assignment to low, intermediate, and high‐risk group, published by the National Cancer Institute (NCI) at the National Institutes of Health (NIH) (<a href="./references#CD010774-bbs2-0055" title="National Cancer Institute (NCI) at the National Institutes of Health (NIH), Physician Data Query(PDQ) . Neuroblastoma treatment. http://www.cancer.gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional (accessed 25 September 2013). ">NCI PDQ 2013</a>), is shown in <a href="#CD010774-tbl-0003">Table 2</a>. </p> <div class="table" id="CD010774-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">The International Neuroblastoma Risk Group (INRG) consensus pretreatment classification schema</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>INRG stage</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Age (months)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Histologic category</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Grade of tumor differentiation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>MYC‐N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>11q aberration</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ploidy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Pretreatment risk group</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Code</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interpretation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L1/L2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ganglioneuroma maturing; ganglioneuroblastoma intermixed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>L1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any, except ganglioneuroma or ganglioneuroblastoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>K</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>L2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any, except ganglioneuroma or ganglioneuroblastoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>≥ 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Ganglioneuroblastoma nodular; neuroblastoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Differentiating</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>E</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>H</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poorly differentiated or undifferentiated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>H</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>M</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperdiploid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diploid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to &lt; 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diploid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>J</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>MS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>&lt; 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Q</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Reference: <a href="./references#CD010774-bbs2-0032" title="CohnSL , PearsonAD , LondonWB , MonclairT , AmbrosPF , BrodeurGM , et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of Clinical Oncology2009;27(2):289‐97. ">Cohn 2009</a> </p> <p>The International Neuroblastoma Risk Group (INRG) consensus classification schema includes the criteria for INRG stage, age, histologic category, grade of tumor differentiation, MYC‐N status, presence/absence of 11q aberrations, and tumor cell ploidy. Sixteen statistically and/or clinically different pretreatment groups of patients (lettered A through R) have been identified using these criteria. The categories are designated as very low (A, B, C), low (D, E, F), intermediate (G, H, I, J), or high (K, N, O, P, Q, R) pretreatment risk subsets. </p> <p>Abbreviations: INRG: International Neuroblastoma Risk Group; MYC‐N: the official gene symbol approved by the Human Genome Organisation (HUGO) Gene Nomenclature Committee (HGNC), which is a short abbreviated form of the gene name 'v‐myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog'; </p> </div> </div> <div class="table" id="CD010774-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Children's Oncology Group (COG) assignment to low, intermediate, and high‐risk group</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> INSS stage</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Age</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MYC‐N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> INPC classification</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> DNA index</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk group</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2A/2B</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 365 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 365 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favorable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 365 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unfavorable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 365 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favorable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 365 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unfavorable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 365 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 548 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 548 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4S</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favorable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>= 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unfavorable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Reference: <a href="./references#CD010774-bbs2-0055" title="National Cancer Institute (NCI) at the National Institutes of Health (NIH), Physician Data Query(PDQ) . Neuroblastoma treatment. http://www.cancer.gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional (accessed 25 September 2013). ">NCI PDQ 2013</a> </p> <p>DNA index: favorable &gt; 1 (hyperdiploid) or &lt; 1 (hypodiploid); unfavorable = 1 (diploid)</p> <p>Abbreviations: COG: Children's Oncology Group; d: days; DNA: deoxyribonucleic acid; INPC: International Neuroblastoma Pathology Committee (also called Shimada system); INSS: The International Neuroblastoma Staging System; MYC‐N: the official gene symbol approved by the Human Genome Organisation (HUGO) Gene Nomenclature Committee (HGNC), which is a short abbreviated form of the gene name 'v‐myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog'; y: years </p> </div> </div> <p>An abdominal mass is the most common presentation of neuroblastoma. In general, neuroblastoma occurs at a single location, usually the medulla of the adrenal gland or along the paravertebral sympathetic chain. As approximately 70% of patients with neuroblastoma have metastatic disease at diagnosis, organ‐specific symptoms may be caused by the local presence of metastases, such as eye problems associated with retrobulbar tumors, pancytopenia associated with bone marrow infiltration, abdominal distension and respiratory problems associated with liver enlargement, and paralysis and Horner syndrome associated with ganglion involvement (<a href="./references#CD010774-bbs2-0055" title="National Cancer Institute (NCI) at the National Institutes of Health (NIH), Physician Data Query(PDQ) . Neuroblastoma treatment. http://www.cancer.gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional (accessed 25 September 2013). ">NCI PDQ 2013</a>). Furthermore, neuroblastoma is associated with general signs and symptoms, such as tiredness, weakness, or pain. Some neuroblastomas regress spontaneously without therapy, whereas others progress and have a fatal outcome despite therapy. One study in infants aged younger than 12 months showed that nearly half of the study population within three years of diagnosis had a spontaneous regression at follow‐up (<a href="./references#CD010774-bbs2-0041" title="HeroB , SimonT , SpitzR , ErnestusK , GnekowAK , Scheel‐WalterHG , et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95‐S and NB97. Journal of Clinical Oncology2008;26(9):1504‐10. ">Hero 2008</a>). A tumor mass may be confirmed on ultrasound, X‐ray, computed tomography, or magnetic resonance imaging. Guidelines for using imaging methods have been developed in response to the increased importance of image‐defined factors in staging and risk assessment (<a href="./references#CD010774-bbs2-0027" title="BrisseHJ , McCarvilleMB , GranataC , KrugKB , Wootton‐GorgesSL , KanegawaK , et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology2011;261(1):243‐57. ">Brisse 2011</a>). The International Neuroblastoma Staging System (INSS) for neuroblastoma is shown in <a href="#CD010774-tbl-0004">Table 3</a>; INSS definitions of treatment response are shown in <a href="#CD010774-tbl-0005">Table 4</a> (<a href="./references#CD010774-bbs2-0029" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a>). </p> <div class="table" id="CD010774-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">The International Neuroblastoma Staging System (INSS)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Stage</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Definition</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localized tumor with complete gross excision, with or without microscopic residual disease; representative ipsilateral lymph nodes negative for tumor microscopically (nodes attached to and removed with the primary tumor may be positive) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localized tumor with incomplete gross excision; representative ipsilateral non‐adherent lymph nodes negative for tumor microscopically </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2B</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localized tumor with or without complete gross excision, with ipsilateral non‐adherent lymph nodes positive for tumor. Enlarged contralateral lymph nodes must be negative microscopically </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unresectable unilateral tumor infiltrating across the midline,<sup>1</sup> with or without regional lymph node involvement; or localized unilateral tumor with contralateral regional lymph node involvement; or midline tumor with bilateral extension by infiltration (unresectable) or by lymph node involvement </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin, and/or other organs (except as defined for stage 4S) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4S</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localized primary tumor (as defined for stages 1, 2A, or 2B), with dissemination limited to skin, liver, and/or bone marrow<sup>2</sup> (limited to infants &lt; 1 year of age) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Reference: <a href="./references#CD010774-bbs2-0029" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a> </p> <p>Note: Multifocal primary tumors (e.g. bilateral adrenal primary tumors) should be staged according to the greatest extent of disease, as defined above, and followed by a subscript letter M (e.g. 3<sub>M</sub>).<br/> <sup>1</sup>The midline is defined as the vertebral column. Tumors originating on one side and crossing the midline must infiltrate to or beyond the opposite side of the vertebral column.<br/> <sup>2</sup>Marrow involvement in stage 4S should be minimal (i.e. &lt; 10% of total nucleated cells identified as malignant on bone marrow biopsy or on marrow aspirate). More extensive marrow involvement would be considered to be stage 4. An MIBG (meta‐iodobenzylguanidine) scan (if performed) should be negative in the marrow. </p> <p>Abbreviations: INSS: The International Neuroblastoma Staging System;</p> </div> </div> <div class="table" id="CD010774-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Response to treatment</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Response</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Primary tumor</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Metastatic sites</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No tumor</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No tumor; catecholamines normal</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very good partial response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased by 90% to 99%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No tumor; catecholamines normal; residual <sup>99</sup>Tc bone changes allowed </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partial response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased by more than 50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All measurable sites decreased by greater than 50%. Bones and bone marrow: number of positive bone sites decreased by greater than 50%; no more than one positive bone marrow site allowed </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal response</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No new lesions; more than 50% reduction in any measurable lesion (primary or metastases) with less than 50% reduction in any other; less than 25% increase in any existing lesion </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No new lesions; less than 50% reduction but less than 25% increase in any existing lesion </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progressive disease</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Any new lesion; greater than 25% increase in any measurable lesion; previous negative marrow positive for tumor </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Reference: <a href="./references#CD010774-bbs2-0029" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a> </p> </div> </div> </section> <section id="CD010774-sec-0018"> <h3 class="title" id="CD010774-sec-0018">Description of the intervention</h3> <section id="CD010774-sec-0019"> <h4 class="title">Intervention</h4> <p>The rapid COJEC schedule comprises the chemotherapeutic agents cisplatin (represented by the first C of the acronym, otherwise abbreviated P), vincristine (O), carboplatin (J), etoposide (E), and cyclophosphamide (C). The schedule is administered in eight cycles separated by intervals of 10 days and is completed within 70 days from the first to the last drug administered. One example of a rapid COJEC chemotherapeutic regimen has been reported by <a href="./references#CD010774-bbs2-0058" title="PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD , et al. High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">Pearson 2008</a>. </p> <p>In patients with high‐risk neuroblastoma, the aim of the rapid COJEC schedule is to administer higher single doses of selected drugs than standard schedules over a substantially shorter treatment period, with shorter intervals between cycles. Shorter intervals and higher doses increase the dose intensity of chemotherapy, making possible earlier myeloablative autologous hematopoietic stem cell transplantation and, possibly, improving survival. However, increased toxicity such as neutropenia may compromise any favorable effect. </p> </section> <section id="CD010774-sec-0020"> <h4 class="title">Comparators</h4> <p>Various standard cumulative chemotherapy schedules are available for induction therapy in patients with high‐risk neuroblastoma prior to myeloablative autologous hematopoietic stem cell transplantation. Standard induction chemotherapy schedules are characterized by several successive administrations of drugs, and the time intervals between the drug applications are planned to allow the bone marrow to recover and to prevent high‐grade toxicities. One frequently reported chemotherapy regimen for children with high‐risk neuroblastoma was developed by the Memorial Sloan‐Kettering Cancer Center in New York. <a href="./references#CD010774-bbs2-0048" title="KushnerBH , LaQuagliaMP , BonillaMA , LindsleyK , RosenfieldN , YehS , et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. Journal of Clinical Oncology1994;12(12):2607‐13. ">Kushner 1994</a> introduced the N6 protocol including seven courses of high‐dose induction chemotherapy, <a href="./references#CD010774-bbs2-0030" title="CheungNK , KushnerBH , LaQuagliaM , KramerK , GollamudiS , HellerG , et al. N7: a novel multi‐modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Medical and Pediatric Oncology2001;36(1):227‐30. ">Cheung 2001</a> introduced the N7 multimodality protocol continuing the same induction chemotherapy, and <a href="./references#CD010774-bbs2-0049" title="KushnerBH , KramerK , LaQuagliaMP , ModakS , YatagheneK , CheungNK . Reduction from seven to five cycles of intensive induction chemotherapy in children with high‐risk neuroblastoma. Journal of Clinical Oncology2004;22(24):4888‐92. ">Kushner 2004</a> reported the use of five instead of seven courses. Severe adverse events associated with such schedules are mainly hematological and include neutropenia (<a href="./references#CD010774-bbs2-0009" title="LadensteinR , ValteauCD , BrockP , YanivI , CastelV , LaureysG , et al. Randomized trial of prophylactic granulocyte colony‐stimulating factor during rapid COJEC induction in pediatric patients with high‐risk neuroblastoma: the European HR‐NBL1/SIOPEN study. Journal of Clinical Oncology2010;28(21):3516‐24. ">Ladenstein 2010</a>). Examples of standard induction chemotherapy schedules available for use in patients with high‐risk neuroblastoma include the following. </p> <p> <ol id="CD010774-list-0001"> <li> <p>The OPEC/OJEC schedule, comprising cisplatin (P), vincristine (O), carboplatin (J), etoposide (E), and cyclophosphamide (C), is administered in seven cycles separated by intervals of 21 days and is completed within 126 days from the first to the last drug administered. One example of a chemotherapeutic OPEC/OJEC regimen has been reported by <a href="./references#CD010774-bbs2-0058" title="PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD , et al. High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">Pearson 2008</a>. </p> </li> <li> <p>Different schedules of the Children's Oncology Group (COG): One example of a chemotherapeutic COG regimen has been reported by <a href="./references#CD010774-bbs2-0051" title="MatthayKK , VillablancaJG , SeegerRC , StramDO , HarrisRE , RamsayNK , et al. Treatment of high‐risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13‐cis‐retinoic acid. Children's Cancer Group. New England Journal of Medicine1999;341(16):1165‐73. ">Matthay 1999</a> and again recently by <a href="./references#CD010774-bbs2-0052" title="MatthayKK , ReynoldsCP , SeegerRC , ShimadaH , AdkinsES , Haas‐KoganD , et al. Long‐term results for children with high‐risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13‐cis‐retinoic acid: a children's oncology group study. Journal of Clinical Oncology2009;27(7):1007‐13. ">Matthay 2009</a>, which comprised three cycles of cisplatin, etoposide, doxorubicin, and ifosfamide. Notice: <a href="./references#CD010774-bbs2-0051" title="MatthayKK , VillablancaJG , SeegerRC , StramDO , HarrisRE , RamsayNK , et al. Treatment of high‐risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13‐cis‐retinoic acid. Children's Cancer Group. New England Journal of Medicine1999;341(16):1165‐73. ">Matthay 1999</a> was included in the Cochrane Review <a href="./references#CD010774-bbs2-0061" title="YalcinB , KremerLC , CaronHN , vanDalenEC . High‐dose chemotherapy and autologous haematopoietic stem cell rescue for children with high‐risk neuroblastoma. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD006301.pub3] ">Yalcin 2013</a>. The objective of this review was to compare the efficacy of high‐dose chemotherapy and autologous bone marrow or stem cell rescue with conventional therapy in children with high‐risk neuroblastoma. Other examples of different COG induction chemotherapy schedules were reported by <a href="./references#CD010774-bbs2-0056" title="ParkJR , ScottJR , StewartCF , LondonWB , NaranjoA , SantanaVM , et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high‐risk neuroblastoma: a Children's Oncology Group study. Journal of Clinical Oncology2011;29(33):4351‐7. ">Park 2011</a> and <a href="./references#CD010774-bbs2-0046" title="KreissmanSG , SeegerRC , MatthayKK , LondonWB , SpostoR , GruppSA , et al. Purged versus non‐purged peripheral blood stem‐cell transplantation for high‐risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncology2013;14(10):999‐1008. ">Kreissman 2013</a>. </p> </li> <li> <p>The Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) ‐ in English: Association for Pediatric Oncology and Hematology ‐ schedule, comprising the alternating of so‐called N5 and N6 cycles. One example of a chemotherapeutic GPOH regimen has been reported by <a href="./references#CD010774-bbs2-0026" title="BertholdF , BoosJ , BurdachS , ErttmannR , HenzeG , HermannJ , et al. Myeloablative megatherapy with autologous stem‐cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high‐risk neuroblastoma: a randomised controlled trial. Lancet Oncology2005;6(9):649‐58. ">Berthold 2005</a> and was used in the NB2004 trial (<a href="./references#CD010774-bbs2-0039" title="Gesellschaft für Pädiatrische Onkologie undHämatologie . NB2004 trial protocol for risk adapted treatment of children with neuroblastoma. http://www.kinderkrebsinfo.de/sites/kinderkrebsinfo/content/e1676/e9032/e1758/e7671/download7673/NB_2004_1.00_komprimiert__ger.pdf2004; Vol. Version: 1.00 (01.09.2004); accessed July 8, 2013. ">GPOH 2004</a>). Notice: <a href="./references#CD010774-bbs2-0026" title="BertholdF , BoosJ , BurdachS , ErttmannR , HenzeG , HermannJ , et al. Myeloablative megatherapy with autologous stem‐cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high‐risk neuroblastoma: a randomised controlled trial. Lancet Oncology2005;6(9):649‐58. ">Berthold 2005</a> was also included in the Cochrane Review <a href="./references#CD010774-bbs2-0061" title="YalcinB , KremerLC , CaronHN , vanDalenEC . High‐dose chemotherapy and autologous haematopoietic stem cell rescue for children with high‐risk neuroblastoma. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD006301.pub3] ">Yalcin 2013</a>. </p> </li> </ol> </p> </section> </section> <section id="CD010774-sec-0021"> <h3 class="title" id="CD010774-sec-0021">How the intervention might work</h3> <p>The administration of drugs in short intervals and at high tolerated doses could interfere with the recovery of cancer cells from toxic chemotherapeutic doses and could result in more cancer cell death. The substantially reduced total time of drug administration might lower the risk of drug resistance. These possible advantages, taken together, could lead to more effective treatment and improved patient survival. </p> </section> <section id="CD010774-sec-0022"> <h3 class="title" id="CD010774-sec-0022">Why it is important to do this review</h3> <p>Rapid COJEC could improve patient survival compared with standard induction therapy, but could also give rise to more frequent and more severe adverse events than standard induction therapy. The efficacy of and the adverse events associated with this therapy should be confirmed in randomized controlled trials. As the rapid COJEC schedule could be investigated in future studies, this review is important in order to evaluate the evidence base for the efficacy and possible adverse events associated with this treatment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010774-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010774-sec-0023"></div> <p>The aim of this study was to evaluate the efficacy and adverse events of the rapid COJEC induction schedule as compared to standard induction schedules in patients with high‐risk neuroblastoma (as defined by the International Neuroblastoma Risk Group (INRG) classification system). Outcomes of interest were complete response, early toxicity and treatment‐related mortality as primary endpoints and overall survival, progression‐ and event‐free survival, late non‐hematological toxicity, and health‐related quality of life as secondary endpoints. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010774-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010774-sec-0024"></div> <section id="CD010774-sec-0025"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010774-sec-0026"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials.</p> </section> <section id="CD010774-sec-0027"> <h4 class="title">Types of participants</h4> <p>Patients with high‐risk neuroblastoma according to the International Neuroblastoma Risk (NRG) Group (<a href="#CD010774-tbl-0002">Table 1</a>) or the Children's Oncology Group (COG) (<a href="#CD010774-tbl-0003">Table 2</a>) classification systems. </p> </section> <section id="CD010774-sec-0028"> <h4 class="title">Types of interventions</h4> <section id="CD010774-sec-0029"> <h5 class="title">Intervention</h5> <p>Rapid COJEC as induction chemotherapy.</p> </section> <section id="CD010774-sec-0030"> <h5 class="title">Comparators</h5> <p>Different standard induction chemotherapy options, including:</p> <p> <ol id="CD010774-list-0002"> <li> <p>the OPEC/OJEC schedule;</p> </li> <li> <p>the COG schedule; and</p> </li> <li> <p>the GPOH schedule<i>.</i> </p> </li> </ol> </p> <p>Rapid COJEC induction chemotherapy is associated with a substantially shorter treatment period, shorter intervals between cycles, and higher single doses of selected drugs than standard schedules. We planned to assess the role of the intervention in the induction period and in the initial treatment response. Consequently, the treatment initiated after the induction period will need to be identical for both the intervention and comparator schedules. </p> </section> </section> <section id="CD010774-sec-0031"> <h4 class="title">Types of outcome measures</h4> <p>Outcomes listed here are not used as criteria for including studies, but are the outcomes of interest within studies identified for inclusion. </p> <section id="CD010774-sec-0032"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010774-list-0003"> <li> <p>Complete response versus other responses such as partial or no response.</p> </li> <li> <p>Early toxicity: adverse events within 90 days of the therapy; incidence of all reported adverse events and severe (grade 3 and 4) events; and incidence of toxicity‐related discontinuations from treatment. Results may be pooled if similar definitions are used in studies. Examples of potentially used classification systems: National Cancer Institute Common Terminology Criteria for Adverse Events (<a href="./references#CD010774-bbs2-0054" title="National Cancer Institute (NCI), Bethesda , MD , USA . Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (accessed 25 September 2013). ">NCI CTCAE 2010</a>) and World Health Organization (WHO) toxicity grading scale for determining the severity of adverse events (<a href="./references#CD010774-bbs2-0044" title="International Clinical Studies Support Center (ICSSC). WHO Toxicity Grading Scale for Determining The Severity of Adverse Events. http://www.icssc.org/Documents/Resources/AEManual2003AppendicesFebruary_06_2003%20final.pdf (accessed 25 September 2013. ">ICSSC 2003</a>). </p> </li> <li> <p>Treatment‐related mortality: incidence of deaths during the induction period that are classified as treatment‐related or attributed to treatment complications. </p> </li> </ul> </p> </section> <section id="CD010774-sec-0033"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010774-list-0004"> <li> <p>Overall survival (OS): death from any cause from the start of rapid COJEC or standard induction therapy. </p> </li> <li> <p>Progression‐free survival (PFS): time free of disease progression (death from all causes or any disease progression) from the start of rapid COJEC or standard induction therapy; patients may still have the disease but their disease is stable or showed a partial response to treatment. </p> </li> <li> <p>Event‐free survival (EFS): time free of any of a group of defined events (death from all causes, any sign of the disease in participants who had a complete response to treatment, any relapse or progression of the disease, or events defined by the individual study protocol) from the start of rapid COJEC or standard induction therapy; patients may still have the disease. </p> </li> <li> <p>Late non‐hematological toxicity such as organ toxicity and secondary malignancy.</p> </li> <li> <p>Health‐related quality of life measured by validated questionnaires and compared between the intervention and control groups. </p> </li> </ul> </p> </section> </section> </section> <section id="CD010774-sec-0034"> <h3 class="title">Search methods for identification of studies</h3> <p>We used the search methods suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010774-bbs2-0050" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>) and by the Cochrane Childhood Cancer Review Group (<a href="./references#CD010774-bbs2-0047" title="KremerLCM , vanDalenEC , MoherD , CaronHN . Cochrane Childhood Cancer Group. About The Cochrane Collaboration 2008, Issue 3. Art. No.: CHILDCA. ">Kremer 2008</a>). We did not apply language restrictions. </p> <section id="CD010774-sec-0035"> <h4 class="title">Electronic searches</h4> <p>We conduced an electronic literature database search in the Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 11) (<a href="./appendices#CD010774-sec-0089">Appendix 1</a>). We searched in MEDLINE (PubMed) for articles published from 1946 to 11 November 2014 by using the search strategy shown in <a href="./appendices#CD010774-sec-0090">Appendix 2</a>. We searched in EMBASE (Ovid) for articles published from 1980 to 11 November 2014 (<a href="./appendices#CD010774-sec-0091">Appendix 3</a>). We tailored the terms and the syntax used for the search in MEDLINE to the requirements of the other two databases. The Cochrane Childhood Cancer Group ran the searches in the three mentioned electronic databases. The review authors ran all other searches. </p> <p>We searched for ongoing trials by scanning two online registries, ClinicalTrials.gov (<a href="./references#CD010774-bbs2-0031" title="NIH National Institutes of Health. ClinicalTrials.gov. http://clinicaltrials.gov/. ">ClinicalTrials.gov 2014</a>) and the World Health Organization International Clinical Trials Registry Platform (<a href="./references#CD010774-bbs2-0045" title="ICTRP International Clinical Trials Registry Platform, WHO World Health Organization. ICTRP Search Platform. http://apps.who.int/trialsearch/. ">ICTRP 2014</a>), on 3 April 2014 using the term 'neuroblastoma' in the search field 'condition' and the term 'rapid cojec' in the search field 'intervention'. </p> <p>We searched for abstracts presented at the annual meetings of the American Society of Clinical Oncology (ASCO), the International Society of Paediatric Oncology (SIOP), and the Advances in Neuroblastoma Research (ANR) (all 2009 to 2013), which were available for online searching. We requested an online search of the ASCO abstracts using the term 'neuroblastoma' AND 'rapid' AND 'cojec' in the search fields 'title' and 'abstract'. We handsearched the SIOP and ANR abstracts. </p> </section> <section id="CD010774-sec-0036"> <h4 class="title">Searching other resources</h4> <p>We searched for information about trials not registered in electronic databases in reference lists of relevant articles and review articles. </p> </section> </section> <section id="CD010774-sec-0037"> <h3 class="title" id="CD010774-sec-0037">Data collection and analysis</h3> <section id="CD010774-sec-0038"> <h4 class="title">Selection of studies</h4> <p>While preparing this systematic review, we endorsed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement, adhered to its principles, and conformed to its checklist (<a href="./references#CD010774-bbs2-0053" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6:e1000097. ">Moher 2009</a>). We downloaded all titles and abstracts retrieved by electronic searching to the reference management database <a href="./references#CD010774-bbs2-0035" title="Thomson Reuters. EndNote. Version X7. New York City: Thomson Reuters, 2014. ">EndNote 2014</a>, removed duplicates, and two review authors independently examined the remaining references. We included a study selection flow chart in the review. We obtained the full texts of potentially relevant references. Two authors independently assessed the eligibility of retrieved papers. Disagreements were resolved by discussion between the two review authors and consultation with a third author if necessary. We documented reasons for exclusion. If we identified multiple reports of one study we used the latest results. We checked the multiple reports for possible duplicate data, addressed the issue, and did not include duplicate data in the analysis. </p> </section> <section id="CD010774-sec-0039"> <h4 class="title">Data extraction and management</h4> <p>For each included study, two authors independently abstracted data on study design, patient characteristics (such as inclusion criteria, age, stage, co‐morbidity, previous treatment, number enrolled in each arm), interventions (such as type of rapid COJEC and standard induction therapy, dose applied, duration of therapy), risk of bias, duration of follow‐up, and outcomes. We resolved differences between review authors by discussion or by appeal to a third author. </p> <p>For time‐to‐event data, such as survival, we extracted the hazard ratio (HR) and its standard error or confidence interval from trial reports; if these were not reported, we estimated the logHR and its standard error using the methods of <a href="./references#CD010774-bbs2-0057" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a> and using the tool provided by <a href="./references#CD010774-bbs2-0060" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>. For dichotomous outcomes (e.g. response, toxicity, and treatment‐related mortality), we extracted the number of patients in each treatment arm who experienced the outcome of interest and the number of patients assessed at endpoint, in order to estimate a risk ratio. For continuous outcomes (e.g. quality of life measures), we planned to extract the final value or change from baseline and corresponding standard deviation of the outcome of interest and the number of patients assessed at endpoint in each treatment arm at the end of follow‐up to estimate the mean difference or standardized mean difference between treatment arms. However, since no data on health‐related quality of life were available this was not applicable. Where possible, all data extracted are those relevant to an intention‐to‐treat analysis, in which all participants are analyzed in the groups to which they were assigned. If this was not possible we stated this. We noted the time points at which outcomes were collected and reported. </p> </section> <section id="CD010774-sec-0040"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors independently appraised the risk of bias in the included studies. We resolved differences between review authors by discussion or by appeal to a third author. We used the items listed in the Cochrane Childhood Cancer Group manual (<a href="./references#CD010774-bbs2-0047" title="KremerLCM , vanDalenEC , MoherD , CaronHN . Cochrane Childhood Cancer Group. About The Cochrane Collaboration 2008, Issue 3. Art. No.: CHILDCA. ">Kremer 2008</a>), which is based on The Cochrane Collaboration's tool for assessing risk of bias (<a href="./references#CD010774-bbs2-0043" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), but the Cochrane Childhood Cancer Group has made some adjustments: </p> <p> <ol id="CD010774-list-0005"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants (performance bias).</p> </li> <li> <p>Blinding of personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias) was assessed for each outcome separately.</p> </li> <li> <p>Incomplete outcome data, such as missing data, was assessed for each outcome separately (attrition bias). </p> </li> <li> <p>Selective reporting, such as not reporting pre‐specified outcomes (reporting bias).</p> </li> <li> <p>Other sources of bias, such as bias related to the specific study design (other bias).</p> </li> </ol> </p> <p>We applied The Cochrane Collaboration's tool for assessing risk of bias (<a href="./references#CD010774-bbs2-0043" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). In general, a 'low risk' of bias is judged if plausible bias is unlikely to seriously alter the results, for example, participants and investigators enrolling participants could not foresee assignment. A 'high risk' of bias is judged if plausible bias seriously weakens confidence in the results, for example, participants or investigators enrolling participants could possibly foresee assignments. 'Unclear' risk of bias is judged if plausible bias raises some doubt about the results, for example, the method of concealment is not described or not described in sufficient detail to allow a definite judgement. In addition to the 'Risk of bias' tables, we included 'methodological quality' summaries. We took into account the results of the 'Risk of bias' assessment when interpreting the results of the review. </p> </section> <section id="CD010774-sec-0041"> <h4 class="title">Measures of treatment effect</h4> <p>For analyses of time‐to‐event data, the primary effect measure was the hazard ratio. If the hazard ratio was not directly given in the publication, we estimated hazard ratios according to the methods proposed by <a href="./references#CD010774-bbs2-0057" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a> and <a href="./references#CD010774-bbs2-0060" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>. We calculated the hazard ratio using the inverse variance method in a random‐effects model. </p> <p>For dichotomous outcomes, the primary effect measure was the risk ratio. We calculated the risk ratio using the Mantel‐Haenszel method in a random‐effects model. We did not observe rare events and thus did not apply the Peto odds ratio method. For outcomes where only one study was available, we were unable to calculate a risk ratio if one of the treatment groups experienced no events, and we used the Fisher's exact test instead. </p> <p>We planned to analyze and present continuous data using the mean difference, if all results were measured on the same scale. If this was not the case, we planned to use the standardized mean difference. However, we did not identify continuous data. </p> </section> <section id="CD010774-sec-0042"> <h4 class="title">Unit of analysis issues</h4> <p>We did not encounter any unit of analysis issues.</p> </section> <section id="CD010774-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>We conformed to The Cochrane Collaboration's principal options for dealing with missing data (<a href="./references#CD010774-bbs2-0043" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We contacted the authors of the included study, <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>, to clarify the methods used to analyze the time‐to‐event data. We contacted the authors of the included study, <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>, to clarify contrasting numbers of patients with respect to overall response in figure 1 and table 5 of the article Pearson et al 2008. We contacted the authors of the ongoing study <a href="./references#CD010774-bbs2-0025" title="LadensteinA . High Risk Neuroblastoma Study 1 (1.5) of SIOP‐Europe (SIOPEN). ClinicalTrials.gov; ID: NCT01704716; URL: http://clinicaltrials.gov/show/NCT01704716 (accessed 2 April 2014). ">HR‐NBL1/SIOPEN</a> to clarify the expected completion of recruiting participants and the expected publication of the analyzed data. There was no need to contact authors with respect to study selection. </p> <p>We completed all analyses on an available case analysis basis, with the exception of two outcomes, the overall survival analysis and event‐free survival analysis. We conducted both of these analyses on an intention‐to‐treat basis, using the methods of <a href="./references#CD010774-bbs2-0057" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a> to obtain the necessary data for the analysis. </p> </section> <section id="CD010774-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess heterogeneity between studies by visual inspection of forest plots, by estimation of the percentage of heterogeneity between trials that cannot be ascribed to sampling variation (I<sup>2</sup> statistic) (<a href="./references#CD010774-bbs2-0042" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>) and, if possible, by subgroup analyses. If there was evidence of substantial heterogeneity, we planned to investigate and report the possible reasons for this. We considered an I<sup>2</sup> value greater than 50% to indicate substantial heterogeneity. However, since only one study was included in this review, this was not applicable. </p> </section> <section id="CD010774-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>In addition to the evaluation of reporting bias as described in the <a href="#CD010774-sec-0040">Assessment of risk of bias in included studies</a> section, we planned to assess reporting bias (such as publication bias, time lag bias, multiple publication bias, location bias, citation bias, language bias) by constructing a funnel plot when there were a sufficient number of included studies (that is at least 10 studies included in a meta‐analysis) because otherwise the power of the tests is too low to distinguish chance from real asymmetry (<a href="./references#CD010774-bbs2-0043" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Since only one study could be included in the review, this was not applicable. </p> </section> <section id="CD010774-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We analyzed the data using <a href="./references#CD010774-bbs2-0059" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013. ">Review Manager 2013</a>. This was done by one author and checked by another. If sufficient clinically similar studies were available, we planned to pool their results, but since only one study was included this was not applicable. We did not identify trials with multiple groups that 'shared' a comparison group, so it was not necessary to divide the 'shared' comparison group into the number of treatment groups and comparisons between each treatment group and treat the split comparison group as independent comparisons. We used random‐effects models with inverse variance weighting for all analyses (<a href="./references#CD010774-bbs2-0034" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). We calculated all risk ratio (RR), hazard ratio (HR), 95% confidence interval (CI), and P values mentioned in the results in <a href="./references#CD010774-bbs2-0059" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013. ">Review Manager 2013</a>, with the exception of the Fisher's exact P value (calculated in statcalc.exe). </p> <p>We used <a href="./references#CD010774-bbs2-0040" title="Information Management System (IMS), The Nordic Cochrane Centre, The Cochrane Collaboration. GRADEpro (GRADE profiler). Version 3.2 for Windows. Copenhagen: Information Management System (IMS), The Nordic Cochrane Centre, The Cochrane Collaboration, 2008. ">GRADEpro 2008</a> to create the 'Summary of findings' table as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010774-bbs2-0043" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We presented complete response, early toxicity, treatment‐related mortality, overall survival, progression‐free survival, event‐free survival, and late non‐hematological toxicity provided that data were presented for both treatment arms. </p> </section> <section id="CD010774-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned a subgroup analysis based on age (younger than 12 months versus 12 months and older). Patients younger than 12 months have a better prognosis than older children. A considerable proportion of patients younger than 12 months have tumor features that are associated with spontaneous regression. As a consequence, the INSS limits stage 4S to infants younger than 12 months of age (<a href="./references#CD010774-bbs2-0029" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a>) and the COG assignment uses the age of 365 days as a cut‐off for stage and risk group assignments (<a href="./references#CD010774-bbs2-0055" title="National Cancer Institute (NCI) at the National Institutes of Health (NIH), Physician Data Query(PDQ) . Neuroblastoma treatment. http://www.cancer.gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional (accessed 25 September 2013). ">NCI PDQ 2013</a>). However, the included study did not provide enough data to be able to do this. </p> </section> <section id="CD010774-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses of studies with low risk of bias versus studies with high or uncertain risk of bias. We identified a single study with an uncertain risk of bias. A sensitivity analysis was not applicable. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010774-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010774-sec-0049"></div> <section id="CD010774-sec-0050"> <h3 class="title">Description of studies</h3> <section id="CD010774-sec-0051"> <h4 class="title">Results of the search</h4> <p>Running the searches in the electronic databases CENTRAL, MEDLINE, and EMBASE yielded a total of 250 references (<a href="#CD010774-fig-0001">Figure 1</a>). We identified one additional reference through searching the ongoing trials registries. We identified two abstracts associated with the publication by Moreno et al 2013 in the proceedings of the Advances in Neuroblastoma Research (ANR) 2010 conference. We added the abstracts to the references of the <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> study. Scanning the conference proceedings of the American Society of Clinical Oncology (ASCO) and the International Society of Paediatric Oncology (SIOP), as well as the reference lists of relevant studies, did not identify any additional references. Following initial screening of the titles, abstracts, or both, we excluded 225 references, which clearly did not meet all criteria required for considering studies for this review. We assessed the 28 remaining references in full, of which four fulfilled all the criteria for considering studies for this review and were thus eligible for inclusion. These four publications described the same study, so the total number of included studies was one (<a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>). The publication by Pearson et al 2008 reported the main information and results of the included RCT. The publication by Moreno et al 2013 updated the data on late toxicity. As mentioned above, two further conference abstracts were linked to Moreno et al 2013. We identified one ongoing study (see <a href="./references#CD010774-sec-0102" title="">Characteristics of ongoing studies</a> table). We excluded the other 23 references. See <a href="#CD010774-fig-0001">Figure 1</a> providing an overview of reference and study selection. </p> <div class="figure" id="CD010774-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010774-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010774-sec-0052"> <h4 class="title">Included studies</h4> <p>The characteristics of the one included study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> are also described in the <a href="./references#CD010774-sec-0100" title="">Characteristics of included studies</a> table. The name of the study is composed of two abbreviations. CCLG stands for Children's Cancer and Leukaemia Group, the trial lead organization. ENSG‐5 stands for European Neuroblastoma Group Fifth Study. </p> <section id="CD010774-sec-0053"> <h5 class="title">Design</h5> <p>We included one study that we judged to be a randomized, prospective, parallel, controlled clinical trial. The study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> enrolled patients from 1990 to 1999. </p> </section> <section id="CD010774-sec-0054"> <h5 class="title">Sample sizes</h5> <p>The study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> randomized 262 patients with high‐risk neuroblastoma to induction chemotherapy, either rapid COJEC (N = 130) or standard OPEC/COJEC (N = 132). </p> </section> <section id="CD010774-sec-0055"> <h5 class="title">Setting</h5> <p>The study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> was conducted as a multi‐center study in 29 centres in Europe including Belgium, Denmark, Ireland, Norway, Sweden, and the UK. The study center was the Children's Cancer and Leukaemia Group located at the University of Leicester in the UK. </p> </section> <section id="CD010774-sec-0056"> <h5 class="title">Participants</h5> <p>The study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> included patients aged 12 months and older and adults who fulfilled the International Neuroblastoma Staging System (INSS) criteria for stage 4 neuroblastoma and who had not received previous chemotherapy for their disease were eligible. Patients with stage 4S neuroblastoma were not eligible. The characteristics of the participants were fairly comparable between the rapid COJEC arm and the standard arm. The median age was 2.86 in the rapid COJEC arm and 2.98 in the standard arm. The proportions in the rapid COJEC arm versus the standard arm were: male gender 58% versus 57%, bone marrow involvement 82% versus 83%, lymph node metastases 62% versus 63%, multiple bone metastases 61% versus 58%. MYC‐N amplified was found more often in the rapid COJEC arm (43%) compared to the standard arm (33%). Follow‐up time was not reported regarding the 262 randomized patients. The median follow‐up of 62 alive patients in the Pearson et al 2008 publication was 12.5 years (range 0 to 16.5). Follow‐up time was not reported regarding the 69 patients eligible for long‐term follow‐up who survived five years. The median follow‐up of 57 analyzed long‐term survivors in the Moreno et al 2013 publication was 12.7 years (6.9 to 16.5). </p> </section> <section id="CD010774-sec-0057"> <h5 class="title">Interventions</h5> <p>The study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> randomized 130 patients to the rapid COJEC arm. The rapid COJEC arm treatment consisted of eight alternating courses given over 10 weeks (see <a href="./references#CD010774-sec-0100" title="">Characteristics of included studies</a> table for more treatment details). </p> <p>The study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> randomized 132 patients to the standard arm. The standard arm treatment consisted of seven alternating courses given over 18 weeks (see <a href="./references#CD010774-sec-0100" title="">Characteristics of included studies</a> table for more treatment details). </p> <p>The study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> assigned all 262 patients to receive the same five different chemotherapeutic agents with almost the same total doses. However, the daily doses and the time schedules were quite different at least for some treatment components. </p> </section> <section id="CD010774-sec-0058"> <h5 class="title">Primary outcome</h5> <p>The study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> reported the following primary outcomes defined by the present review: </p> <p> <ul id="CD010774-list-0006"> <li> <p>Complete response</p> </li> <li> <p>Early toxicity</p> </li> <li> <p>Treatment‐related mortality</p> </li> </ul> </p> </section> <section id="CD010774-sec-0059"> <h5 class="title">Secondary outcomes</h5> <p>The study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> reported the following secondary outcomes defined by the present review: </p> <p> <ul id="CD010774-list-0007"> <li> <p>Overall survival</p> </li> <li> <p>Event‐free survival</p> </li> <li> <p>Late non‐hematological toxicity (updated by the publication by Moreno et al 2013)</p> </li> </ul> </p> <p>Progression‐free survival and health‐related quality of life were not reported.</p> </section> </section> <section id="CD010774-sec-0060"> <h4 class="title">Excluded studies</h4> <p>We excluded 23 publications (<a href="#CD010774-fig-0001">Figure 1</a>). We determined the reasons for exclusions as follows: </p> <p> <ul id="CD010774-list-0008"> <li> <p>not population of interest: high‐risk neuroblastoma (N = 0);</p> </li> <li> <p>not intervention of interest: not rapid COJEC as a induction chemotherapy (N = 15);</p> </li> <li> <p>not comparator of interest: standard induction chemotherapy such as OPEC/OJEC, COG, or GPOH schedules (N = 3); </p> </li> <li> <p>not outcome of interest (N = 0);</p> </li> <li> <p>not publication type or study type of interest such as systematic or nonsystematic review, editorial, letter, duplicate data, or not a randomized controlled trial (N = 5). </p> </li> </ul> </p> <p>We described the excluded studies in the <a href="./references#CD010774-sec-0101" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD010774-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>The 'Risk of bias' table <a href="./references#CD010774-sec-0100" title="">Characteristics of included studies</a> provides details of each item of the 'Risk of bias' tool for randomized controlled trials. <a href="#CD010774-fig-0002">Figure 2</a> and <a href="#CD010774-fig-0003">Figure 3</a> provide an overview. </p> <div class="figure" id="CD010774-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010774-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010774-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010774-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010774-sec-0062"> <h4 class="title">Allocation</h4> <p>In the study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>, allocation concealment was achieved by telephone contact to a study center (N = 251) and by sealed envelopes during out‐of‐hours (N = 11). We judged a low risk for the 251 patients and an unclear risk for the 11 patients since it was not reported if the envelopes were opaque. However, since it was unclear if the sequence generation was random we judged the risk of selection bias to be unclear. </p> </section> <section id="CD010774-sec-0063"> <h4 class="title">Blinding</h4> <p>The study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> did not report on blinding of participants and personnel, so we judged an unclear risk of performance bias. Blinding of outcome assessors was also not reported, so we judged the risk of detection bias to be unclear, with the exception of the risk of detection bias for overall survival. Since blinding of the outcome assessor is not relevant for this outcome here we judged the risk of detection bias to be low.  </p> </section> <section id="CD010774-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p>For all reported outcomes, i.e. complete response, early toxicity, treatment‐related death, overall survival, event‐free survival, and late non‐hematological toxicities, we judged the risk of attrition bias to be high. </p> </section> <section id="CD010774-sec-0065"> <h4 class="title">Selective reporting</h4> <p>In <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>, we did not identify any sign of selective reporting comparing the outcomes and methods of the publication with those of published protocol items at ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/ct2/show/NCT00365755" target="_blank">http://www.clinicaltrials.gov/ct2/show/NCT00365755</a>) and at the National Cancer Institute (<a href="http://www.cancer.gov/clinicaltrials/search/view?cdrid=454576%26version=HealthProfessional" target="_blank">http://www.cancer.gov/clinicaltrials/search/view?cdrid=454576&amp;version=HealthProfessional</a>), so we judged this to be a low risk of reporting bias. </p> </section> <section id="CD010774-sec-0066"> <h4 class="title">Other potential sources of bias</h4> <p>We judged the risk for other potential sources of bias to be unclear. A full explanation can be found in the risk of bias part of the table of included studies.  </p> </section> </section> <section id="CD010774-sec-0067"> <h3 class="title" id="CD010774-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD010774-tbl-0001"><b>Summary of findings for the main comparison</b> Rapid COJEC compared to standard induction therapies for high‐risk neuroblastoma</a> </p> <section id="CD010774-sec-0068"> <h4 class="title">Primary outcomes</h4> <section id="CD010774-sec-0069"> <h5 class="title">Complete response</h5> <p>The original article of Pearson et al 2008 reported different numbers regarding response in table 5 and figure 1. After asking the authors for clarification, it became clear that none of the options mentioned in the original article were correct. The authors provided us with the correct numbers, which we used in our analysis. </p> <p>In the study (<a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>), 62% of patients (80 of 130) in the rapid COJEC arm and 68% of patients (90 of 132) in the standard arm were assessed for overall response. A complete response was achieved by 45% (36 of 80) of patients in the rapid COJEC arm and 46% (41 of 90) of patients in the standard arm, as confirmed by the authors of the article by Pearson et al 2008. In the available data analysis, we chose complete response as the favorable outcome that was compared to all other responses including very good partial response, partial response, mixed response, no response, and progressive disease. The risk ratio of 0.99 (95% confidence interval (CI) 0.71 to 1.38, P value = 0.94) was not statistically significant (<a href="./references#CD010774-fig-0007" title="">Analysis 1.1</a>; <a href="#CD010774-fig-0004">Figure 4</a>). Please note that due to the nature of this measurement (that is, the number of patients with a complete remission) a high event rate is favorable. Therefore, in the figure of this analysis 'favors standard' is on the left and 'favors rapid COJEC' is on the right, as opposed to the figures for the other analyses. </p> <div class="figure" id="CD010774-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Rapid COJEC versus standard induction, outcome: 1.1 Complete response." data-id="CD010774-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rapid COJEC versus standard induction, outcome: 1.1 Complete response. </p> </div> </div> </div> </section> <section id="CD010774-sec-0070"> <h5 class="title">Early toxicity</h5> <p>In the study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>, the authors reported toxic effects during preoperative chemotherapy. For each subgroup, we presented the data from the rapid COJEC arm versus the data from the standard arm. </p> <p>Febrile neutropenia (two or more episodes): 94% (116 of 123) versus 77% (96 versus 125). The relative risk between the two event rates was statistically significant: risk ratio 1.23 (95% CI 1.10 to 1.36, P value = 0.0001) (<a href="./references#CD010774-fig-0008" title="">Analysis 1.2</a>; <a href="#CD010774-fig-0005">Figure 5</a>). Please note that this was an available data analysis. </p> <div class="figure" id="CD010774-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Rapid COJEC versus standard induction, outcome: 1.2 Early toxicities." data-id="CD010774-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rapid COJEC versus standard induction, outcome: 1.2 Early toxicities. </p> </div> </div> </div> <p>Proven fungal infections: 2% (2 of 100) versus 0.8% (1 of 125). The relative risk between the two event rates was not statistically significant: risk ratio 2.50 (95% CI 0.23 to 27.18, P value = 0.45) (<a href="./references#CD010774-fig-0008" title="">Analysis 1.2</a>; <a href="#CD010774-fig-0005">Figure 5</a>). Please note that this was an available data analysis. </p> <p>Number of patients with septicemia (one or more episodes): 45% (55 of 122) versus 28% (35 of 125). The relative risk between the two event rates was statistically significant: risk ratio 1.61 (95% CI 1.14 to 2.27, P value = 0.006) (<a href="./references#CD010774-fig-0008" title="">Analysis 1.2</a>; <a href="#CD010774-fig-0005">Figure 5</a>). Please note that this was an available data analysis. </p> <p>Grade 3 or 4 gastrointestinal toxic effects: 35% (43 of 122) versus 25% (31 of 124). The relative risk between the two event rates was not statistically significant: risk ratio 1.41 (95% CI 0.96 to 2.08, P value = 0.08) (<a href="./references#CD010774-fig-0008" title="">Analysis 1.2</a>; <a href="#CD010774-fig-0005">Figure 5</a>). Please note that this was an available data analysis. </p> <p>Renal toxic effects, where glomerular filtration rate (GFR) &lt; 80 ml/min per body surface area of 1.73m<sup>2</sup>: (37% (46 of 124) versus 17% (21 of 124). The relative risk between the two event rates was statistically significant: risk ratio 2.19 (95% CI 1.39 to 3.44, P value = 0.0007) (<a href="./references#CD010774-fig-0008" title="">Analysis 1.2</a>; <a href="#CD010774-fig-0005">Figure 5</a>). Please note that this was an available data analysis. </p> <p>Grade 3 or 4 neurological toxic effects: 4.9% (6 of 122) versus 1.6% (2 of 125). The relative risk between the two event rates was not statistically significant: risk ratio 3.07 (95% CI 0.63 to 14.93, P value = 0.16) (<a href="./references#CD010774-fig-0008" title="">Analysis 1.2</a>; <a href="#CD010774-fig-0005">Figure 5</a>). Please note that this was an available data analysis. </p> <p>Ototoxicity (Brock 2 to 4): 5.8% (4 of 69) versus 5.6% (4 of 72). The relative risk between the two event rates was not statistically significant: risk ratio 1.04 (95% CI 0.27 to 4.01, P value = 0.95) (<a href="./references#CD010774-fig-0008" title="">Analysis 1.2</a>; <a href="#CD010774-fig-0005">Figure 5</a>). Please note that this was an available data analysis. </p> </section> <section id="CD010774-sec-0071"> <h5 class="title">Treatment‐related mortality</h5> <p>The authors of the study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> reported that treatment‐related deaths occurred in 4% of patients (5 of 119) in the rapid COJEC arm and in 3% of patients (4 of 115) in the standard arm. In the available data analysis, the risk ratio of 1.21 (95% CI 0.33 to 4.39, P value = 0.77) was not statistically significant (<a href="./references#CD010774-fig-0009" title="">Analysis 1.3</a>; <a href="#CD010774-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD010774-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Rapid COJEC versus standard induction, outcome: 1.3 Treatment‐related mortality." data-id="CD010774-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rapid COJEC versus standard induction, outcome: 1.3 Treatment‐related mortality. </p> </div> </div> </div> </section> </section> <section id="CD010774-sec-0072"> <h4 class="title">Secondary outcomes</h4> <section id="CD010774-sec-0073"> <h5 class="title">Overall survival</h5> <p>The overall survival analysis was done on an intention‐to‐treat basis. In the study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>, the hazard ratio of overall survival of 0.83 (95% CI 0.63 to 1.10, P value = 0.19) was not statistically significant (<a href="./references#CD010774-fig-0010" title="">Analysis 1.4</a>). We used Parmar's method to obtain the necessary data for the analysis. </p> </section> <section id="CD010774-sec-0074"> <h5 class="title">Progression‐free survival</h5> <p>We did not find data on progression‐free survival in the study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>. </p> </section> <section id="CD010774-sec-0075"> <h5 class="title">Event‐free survival</h5> <p>We conducted the event‐free survival analysis on an intention‐to‐treat basis. In the study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>, the hazard ratio of event‐free survival of 0.86 (95% CI 0.65 to 1.13, P value = 0.28) was not statistically significant (<a href="./references#CD010774-fig-0011" title="">Analysis 1.5</a>). We used Parmar's method to obtain the necessary data for the analysis. </p> </section> <section id="CD010774-sec-0076"> <h5 class="title">Late non‐hematological toxicity</h5> <p>In the study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>, the authors reported data on late non‐hematological toxicity in the publication by Moreno et al 2013. The authors considered data from patients who survived at least five years after diagnosis. They identified 69 of 262 patients as eligible, excluded data from 12 patients, and finally analyzed data from 57 patients. After a median follow‐up of 12.7 years (6.9 to 16.5), the following number of adverse events/total number of patients in the particular organ subgroup were observed in the rapid COJEC arm versus the standard arm. The number of events present the number of patients with at least one complication. Neurocognitive issues comprise behavioral, speech, or learning difficulties. </p> <p>Complications independent of the type of organ system affected: 75.7% (28 of 37) versus 80.0% (16 of 20). The relative risk between the two event rates was not statistically significant: risk ratio 0.95 (95% CI 0.71 to 1.26, P value = 0.70) (<a href="./references#CD010774-fig-0012" title="">Analysis 1.6</a>). </p> <p>Renal toxicity, glomerular filtration rate less than 80 ml/(min * 1.73 m<sup>2</sup>): 8.1% (3 of 37) versus 25% (5 of 20). The relative risk between the two event rates was not statistically significant: risk ratio 0.32 (95% CI 0.09 to 1.22, P value = 0.10) (<a href="./references#CD010774-fig-0012" title="">Analysis 1.6</a>). </p> <p>Hearing loss: 54.1% (20 of 37) versus 40.0% (8 of 20). The relative risk between the two event rates was not statistically significant: risk ratio 1.35 (95% CI 0.73 to 2.50, P value = 0.34) (<a href="./references#CD010774-fig-0012" title="">Analysis 1.6</a>). </p> <p>Endocrine complication: 18.9% (7 of 37) versus 45.0% (9 of 20). The event rate in the rapid COJEC arm was statistically significantly lower than in the standard arm: risk ratio 0.42 (95% CI 0.18 to 0.96, P value = 0.04) (<a href="./references#CD010774-fig-0012" title="">Analysis 1.6</a>). </p> <p>Neurocognitive complication: 10.8% (4 of 37) versus 40.0% (8 of 20). The event rate in the rapid COJEC arm was statistically significantly lower than in the standard arm: risk ratio 0.27 (95% CI 0.09 to 0.79, P value = 0.02) (<a href="./references#CD010774-fig-0012" title="">Analysis 1.6</a>). </p> <p>Second malignancies: 8.1% (3 of 37) in the rapid COJEC arm versus 0% (0 of 20) in the standard arm had second malignancies. Since in one of the treatment groups there were no events we were unable to calculate a relative risk, so we used Fisher's exact test instead: Fisher's exact P value = 0.55. The three second malignancies were osteosarcoma, carcinoma of the parotid gland, and anaplastic ependymoma. They developed 10.1 to 11.4 years after the neuroblastoma diagnosis. It should be noted that one patient in the standard arm developed a rhabdomyosarcoma 2.3 years after the neuroblastoma diagnosis. This patient was not included in this analysis as she died before becoming a long‐term survivor (i.e. five years from neuroblastoma diagnosis). </p> </section> <section id="CD010774-sec-0077"> <h5 class="title">Health‐related quality of life</h5> <p>We did not find data on health‐related quality of life in the study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010774-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010774-sec-0078"></div> <section id="CD010774-sec-0079"> <h3 class="title" id="CD010774-sec-0079">Summary of main results</h3> <p>This systematic review evaluated the current state of evidence on the efficacy of rapid COJEC versus standard induction therapy in patients diagnosed with high‐risk neuroblastoma. </p> <p>We identified one randomized controlled trial (RCT) (<a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>), which included 262 patients with high‐risk neuroblastoma who received induction chemotherapy by a randomized allocation to rapid COJEC (n = 130) or standard induction therapy (n = 132). The primary objectives of study <a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a> were to "to compare survival, treatment response and dose‐limiting treatment‐related severe adverse events in patients with high‐risk neuroblastoma receiving induction therapy with either rapid COJEC or a standard schedule". </p> <p>There was no statistically significant difference between the treatment groups in complete response (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.71 to 1.38, P value = 0.94, low quality of evidence), treatment‐related mortality (RR 1.21, 95% CI 0.33 to 4.39, P value = 0.77, low quality evidence), overall survival (hazard ratio (HR) 0.83, 95% CI 0.63 to 1.10, P value = 0.19, low quality of evidence), and event‐free survival (HR 0.86, 95% CI 0.65 to 1.13, P value = 0.28, low quality of evidence). We calculated the HRs using the complete follow‐up period of the trial. </p> <p>Both treatment arms received the same treatment including the same drugs and the same total dose. Therefore, adverse events caused by the type or dose of a chemotherapeutic substance are not to be expected different between the two arms. Nevertheless, the increased time intensity in the rapid COJEC arm or the longer drug application period in the standard arm may cause differences in the frequency of adverse events between the two arms. </p> <p>With regard to early toxicities (during pre‐operative chemotherapy) the study provided data on febrile neutropenia (two or more episodes), proven fungal infections, septicemia (one or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate &lt; 80 ml/min per body surface area of 1.73 m<sup>2</sup>), neurological toxicity (grade 3 or 4), and ototoxicity (Brock grade 2 to 4). For febrile neutropenia, septicemia, and renal toxicity, we identified a statistically significant difference in favor of the standard treatment arm (low quality evidence); for all other early toxicities, we identified no statistically significant difference between treatment groups (low quality evidence). </p> <p>With regard to late non‐hematological toxicities (median follow‐up 12.7 years; range 6.9 to 16.5 years), the study provided data on any complication, renal toxicity (glomerular filtration rate &lt; 80 ml/min per body surface area of 1.73 m<sup>2</sup>), ototoxicity (Brock grade 1 to 4), endocrine complications (see <a href="./references#CD010774-sec-0100" title="">Characteristics of included studies</a> table for included disorders), neurocognitive complications (i.e. behavioral, speech, or learning difficulties), and second malignancies. For endocrine complications and neurocognitive complications we found a statistically significant difference in favor of the rapid COJEC arm (low quality evidence); for all other late non‐hematological toxicities, we identified no statistically significant difference between treatment groups (low quality evidence). </p> <p>No data were available for the other outcomes of interest (i.e. progression‐free survival and health‐related quality of life) (see <a href="./full#CD010774-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD010774-sec-0080"> <h3 class="title" id="CD010774-sec-0080">Overall completeness and applicability of evidence</h3> <p>The inclusion of only one study in the present review limits the inferences we can make from the extracted data. 'No evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. The reason that no statistically significant difference between study groups was identified could be the fact that the number of patients included was too small to detect a difference between the treatment groups (i.e. low power). Although the exact length of follow‐up for the patients of interest was not mentioned, it could have been too short to detect a significant difference between the treatment groups. </p> <p>Furthermore, patients were treated in the time period from 1990 to 1999 (<a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>). The applicability of these data to current clinical practice is considerably restricted as medical knowledge and terms of health care have progressed and changed significantly since then. Thus, the results may not be applicable to patients who are treated today. Since only one eligible study was identified we could not assess this issue. </p> <p>Another point is that the included RCT used an age of one year as the cut‐off point for pre‐treatment risk stratification. Recently, the age cut‐off for high‐risk disease was changed from one year to 18 months (<a href="./references#CD010774-bbs2-0032" title="CohnSL , PearsonAD , LondonWB , MonclairT , AmbrosPF , BrodeurGM , et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of Clinical Oncology2009;27(2):289‐97. ">Cohn 2009</a>). As a result, it is possible that patients with what is now classified as intermediate‐risk disease were included in the high‐risk groups. Consequently the relevance of the results of these studies to current practice can be questioned. Survival rates may be overestimated due to the inclusion of patients with intermediate‐risk disease. </p> <p>Finally, the included study did not provide data on progression‐free survival and health‐related quality of life in these patients. As a result we cannot make any conclusions regarding those outcomes, but they are of course important for clinical practice. </p> <p>As reported by Moreno et al in their 2013 publication (<a href="./references#CD010774-bbs2-0001" title="MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract PL36. Long‐term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:105. MorenoL , VaidyaS , PinkertonR , LewisIJ , ImesonJ , EllershawC , et al. Abstract SEL10. Persistence of disease in long‐term survivors of high‐risk neuroblastoma. Analysis of ENSG5 cooperative trial. The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden. Stockholm: Advances in Neuroblastoma Research Association (ANRA), 2010:136. MorenoL , VaidyaSJ , PinkertonCR , LewisIJ , ImesonJ , MachinD , et al. Long‐term follow‐up of children with high‐risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood and Cancer2013;60(7):1135‐40. PearsonAD , PinkertonCR , LewisIJ , ImesonJ , EllershawC , MachinD . High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology2008;9(3):247‐56. ">CCLG‐ENSG‐5</a>), 77.2% of long‐term survivors (44 of 57) treated with either treatment option had some sort of complication and as 19.3% (11 of 57) had severe complications, tight monitoring of late toxicity is recommended for all patients having received rapid COJEC or standard induction therapy. </p> <p>We only included RCTs since it is widely recognized that a RCT is the only study design that can be used to obtain unbiased evidence on the use of different treatment options, provided that the design and execution of the RCTs are adequate. However, even though RCTs are the highest level of evidence, it should be recognized that data from non‐randomized studies are available. </p> </section> <section id="CD010774-sec-0081"> <h3 class="title" id="CD010774-sec-0081">Quality of the evidence</h3> <p>The risk of bias in the included study was difficult to assess, in part due to a lack of reporting. As a result, the presence of selection bias, performance bias, detection bias (for outcomes other than overall survival), and other bias could not be ruled out. There was a high risk of attrition bias for all included outcomes. However, at the moment this is the best available evidence from RCTs comparing the efficacy of rapid COJEC versus standard induction therapy in high‐risk neuroblastoma patients. </p> <p>Based on the GRADE assessments, for which we have looked at the five GRADE considerations study limitations, consistency of effect, imprecision, indirectness, and publication bias, we judged the quality of the evidence for the outcomes for which data were available as being low; we downgraded for risk of bias and imprecision (see <a href="./full#CD010774-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD010774-sec-0082"> <h3 class="title" id="CD010774-sec-0082">Potential biases in the review process</h3> <p>One of the strengths of this systematic review is the broadness of the search strategy such that study retrieval bias is very unlikely. Nevertheless, there remains a slight possibility that an unknown number of studies were not registered and not published. Duplicate publication bias is very unlikely because we searched for follow‐up papers of a single study, to ensure that we included the updated version, and we excluded secondary analyses of registers or databases, which may use data that have been published previously by individual contributing study centers. Overall, the possible presence of reporting bias seems to be low. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010774-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/urn:x-wiley:14651858:media:CD010774:CD010774-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_t/tCD010774-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010774-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010774-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/urn:x-wiley:14651858:media:CD010774:CD010774-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_t/tCD010774-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010774-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010774-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/urn:x-wiley:14651858:media:CD010774:CD010774-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_t/tCD010774-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010774-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010774-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/urn:x-wiley:14651858:media:CD010774:CD010774-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_t/tCD010774-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Rapid COJEC versus standard induction, outcome: 1.1 Complete response." data-id="CD010774-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rapid COJEC versus standard induction, outcome: 1.1 Complete response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010774-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/urn:x-wiley:14651858:media:CD010774:CD010774-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_t/tCD010774-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Rapid COJEC versus standard induction, outcome: 1.2 Early toxicities." data-id="CD010774-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rapid COJEC versus standard induction, outcome: 1.2 Early toxicities. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010774-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/urn:x-wiley:14651858:media:CD010774:CD010774-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_t/tCD010774-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Rapid COJEC versus standard induction, outcome: 1.3 Treatment‐related mortality." data-id="CD010774-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rapid COJEC versus standard induction, outcome: 1.3 Treatment‐related mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010774-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/urn:x-wiley:14651858:media:CD010774:CD010774-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_t/tCD010774-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rapid COJEC versus standard induction, Outcome 1 Complete response." data-id="CD010774-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Rapid COJEC versus standard induction, Outcome 1 Complete response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/references#CD010774-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010774-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/urn:x-wiley:14651858:media:CD010774:CD010774-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_t/tCD010774-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rapid COJEC versus standard induction, Outcome 2 Early toxicities." data-id="CD010774-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Rapid COJEC versus standard induction, Outcome 2 Early toxicities.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/references#CD010774-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010774-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/urn:x-wiley:14651858:media:CD010774:CD010774-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_t/tCD010774-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rapid COJEC versus standard induction, Outcome 3 Treatment‐related mortality." data-id="CD010774-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Rapid COJEC versus standard induction, Outcome 3 Treatment‐related mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/references#CD010774-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010774-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/urn:x-wiley:14651858:media:CD010774:CD010774-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_t/tCD010774-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rapid COJEC versus standard induction, Outcome 4 Overall survival." data-id="CD010774-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Rapid COJEC versus standard induction, Outcome 4 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/references#CD010774-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010774-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/urn:x-wiley:14651858:media:CD010774:CD010774-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_t/tCD010774-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rapid COJEC versus standard induction, Outcome 5 Event‐free survival." data-id="CD010774-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Rapid COJEC versus standard induction, Outcome 5 Event‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/references#CD010774-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010774-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/urn:x-wiley:14651858:media:CD010774:CD010774-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_t/tCD010774-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rapid COJEC versus standard induction, Outcome 6 Late non‐hematological toxicities." data-id="CD010774-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Rapid COJEC versus standard induction, Outcome 6 Late non‐hematological toxicities. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/references#CD010774-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/media/CDSR/CD010774/image_n/nCD010774-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010774-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Rapid COJEC compared to standard induction therapies for high‐risk neuroblastoma</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Rapid COJEC compared to standard induction therapies for high‐risk neuroblastoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with high‐risk neuroblastoma<br/> <b>Settings:</b> pediatric oncology departments<br/> <b>Intervention:</b> rapid COJEC<br/> <b>Comparison:</b> standard induction therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Standard induction therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Rapid COJEC </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>456 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>451 per 1000</b> <br/> (323 to 629) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> <br/> (0.71 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of follow‐up was not reported regarding the 262 randomized patients; median follow‐up of 62 alive patients was 12.5 years (range 0 to 16.5 years) </p> <p>This was an available data analysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Early toxicities (during preoperative chemotherapy): febrile neutropenia (2 or more episodes), proven fungal infections, septicemia (1 or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate &lt; 80 ml/min per body surface area of 1.73 m<sup>2</sup>), neurological toxicity (grade 3 or 4), ototoxicity (Brock grade 2 to 4)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of follow‐up was not reported regarding the 262 randomized patients; median follow‐up of 62 alive patients was 12.5 years (range 0 to 16.5 years) </p> <p>Febrile neutropenia: there was a significant difference in favor of the standard induction therapy arm (RR 1.23, 95% CI 1.10 to 1.36) </p> <p>Proven fungal infections: no significant difference between treatment groups (RR 2.50, 95% CI 0.23 to 27.18) </p> <p>Septicemia: there was a significant difference in favor of the standard induction therapy arm (RR 1.61, 95% CI 1.14 to 2.27) </p> <p>Gastrointestinal toxicity: no significant difference between treatment groups (RR 1.41, 95% CI 0.96 to 2.08) </p> <p>Renal toxicity: there was a significant difference in favor of the standard induction therapy arm (RR 2.19, 95% CI 1.39 to 3.44) </p> <p>Neurological toxicity: no significant difference between treatment groups (RR 3.07, 95% CI 0.63 to 14.93) </p> <p>Ototoxicity: no significant difference between treatment groups (RR 1.04, 95% CI 0.27 to 4.01) </p> <p>These were all available data analyses</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐related mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> <br/> (11 to 153) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> <br/> (0.33 to 4.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of follow‐up was not reported regarding the 262 randomized patients; median follow‐up of 62 alive patients was 12.5 years (range 0 to 16.5 years) </p> <p>This was an available data analysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>811 per 1000</b><sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>749 per 1000</b> <br/> (649 to 840) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.83</b> <br/> (0.63 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of follow‐up was not reported regarding the 262 randomized patients; median follow‐up of 62 alive patients was 12.5 years (range 0 to 16.5 years) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information on this outcome was provided</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Event‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>818 per 1000</b><sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>769 per 1000</b> <br/> (670 to 854) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.86</b> <br/> (0.65 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of follow‐up was not reported regarding the 262 randomized patients; median follow‐up of 62 alive patients was 12.5 years (range 0 to 16.5 years) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Late non‐hematological toxicities: any complication, renal toxicity (Glomerular Filtration Rate &lt; 80 ml/min per body surface area of 1.73 m<sup>2</sup>), ototoxicity (Brock grade 1 to 4), endocrine complications (see table of included studies for included disorders), neurocognitive complications (i.e. behavioral, speech, or learning difficulties), and second malignancies</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of follow‐up was not reported regarding the 69 patients eligible for late toxicities (i.e. at least 5‐year survivors); median follow‐up for the 57 analyzed long‐term survivors was 12.7 years (6.9 to 16.5 years) </p> <p>Any complication: no significant difference between treatment groups (RR 0.95, 95% CI 0.71 to 1.26) </p> <p>Renal toxicity: no significant difference between treatment groups (RR 0.32, 95% CI 0.09 to 1.22) </p> <p>Ototoxicity: no significant difference between treatment groups (RR 1.35, 95% CI 0.73 to 2.50) </p> <p>Endocrine complications: there was a significant difference in favor of the rapid COJEC arm (RR 0.42, 95% CI 0.18 to 0.96) </p> <p>Neurocognitive complications: there was a significant difference in favor of the rapid COJEC arm (RR 0.27, 95% CI 0.09 to 0.79) </p> <p>Second malignancies: no significant difference between treatment groups (Fischer's exact P value = 0.55) </p> <p>These were all available data analyses</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR:</b> hazard ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The assumed risk is based on the prevalence in the control group of the included study.<br/> <sup>2</sup>The presence of selection bias, performance bias, detection bias, and other bias was unclear; there was a high risk of attrition bias.<br/> <sup>3</sup>The total number of events was fewer than 300 (the threshold rule‐of‐thumb value stated in the GRADEpro software).<br/> <sup>4</sup>The assumed risk is based on the number of events in the control group at the final time point of the survival curve presented in the included study.<br/> <sup>5</sup>The presence of selection bias, performance bias, and other bias was unclear; there was a high risk of attrition bias.<br/> <sup>6</sup>As yet no threshold rule‐of‐thumb value for the minimal number of events for time‐to‐event data is included in the GRADEpro software; however, since this is a small study and the 95% confidence interval include values both favoring the intervention and the control treatment, we downgraded for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Rapid COJEC compared to standard induction therapies for high‐risk neuroblastoma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010774-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">The International Neuroblastoma Risk Group (INRG) consensus pretreatment classification schema</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>INRG stage</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Age (months)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Histologic category</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Grade of tumor differentiation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>MYC‐N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>11q aberration</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ploidy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Pretreatment risk group</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Code</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interpretation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L1/L2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ganglioneuroma maturing; ganglioneuroblastoma intermixed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>L1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any, except ganglioneuroma or ganglioneuroblastoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>K</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>L2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any, except ganglioneuroma or ganglioneuroblastoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>≥ 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Ganglioneuroblastoma nodular; neuroblastoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Differentiating</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>E</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>H</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poorly differentiated or undifferentiated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>H</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>M</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperdiploid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diploid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to &lt; 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diploid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>J</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>O</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>MS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>&lt; 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Q</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Reference: <a href="./references#CD010774-bbs2-0032" title="CohnSL , PearsonAD , LondonWB , MonclairT , AmbrosPF , BrodeurGM , et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of Clinical Oncology2009;27(2):289‐97. ">Cohn 2009</a> </p> <p>The International Neuroblastoma Risk Group (INRG) consensus classification schema includes the criteria for INRG stage, age, histologic category, grade of tumor differentiation, MYC‐N status, presence/absence of 11q aberrations, and tumor cell ploidy. Sixteen statistically and/or clinically different pretreatment groups of patients (lettered A through R) have been identified using these criteria. The categories are designated as very low (A, B, C), low (D, E, F), intermediate (G, H, I, J), or high (K, N, O, P, Q, R) pretreatment risk subsets. </p> <p>Abbreviations: INRG: International Neuroblastoma Risk Group; MYC‐N: the official gene symbol approved by the Human Genome Organisation (HUGO) Gene Nomenclature Committee (HGNC), which is a short abbreviated form of the gene name 'v‐myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog'; </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">The International Neuroblastoma Risk Group (INRG) consensus pretreatment classification schema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010774-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Children's Oncology Group (COG) assignment to low, intermediate, and high‐risk group</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> INSS stage</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Age</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MYC‐N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> INPC classification</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> DNA index</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk group</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2A/2B</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 365 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 365 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favorable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 365 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unfavorable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 365 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favorable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 365 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unfavorable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 365 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 548 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 548 d to 21 y</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4S</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favorable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>= 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unfavorable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 365 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amplified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Reference: <a href="./references#CD010774-bbs2-0055" title="National Cancer Institute (NCI) at the National Institutes of Health (NIH), Physician Data Query(PDQ) . Neuroblastoma treatment. http://www.cancer.gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional (accessed 25 September 2013). ">NCI PDQ 2013</a> </p> <p>DNA index: favorable &gt; 1 (hyperdiploid) or &lt; 1 (hypodiploid); unfavorable = 1 (diploid)</p> <p>Abbreviations: COG: Children's Oncology Group; d: days; DNA: deoxyribonucleic acid; INPC: International Neuroblastoma Pathology Committee (also called Shimada system); INSS: The International Neuroblastoma Staging System; MYC‐N: the official gene symbol approved by the Human Genome Organisation (HUGO) Gene Nomenclature Committee (HGNC), which is a short abbreviated form of the gene name 'v‐myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog'; y: years </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Children's Oncology Group (COG) assignment to low, intermediate, and high‐risk group</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010774-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">The International Neuroblastoma Staging System (INSS)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Stage</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Definition</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localized tumor with complete gross excision, with or without microscopic residual disease; representative ipsilateral lymph nodes negative for tumor microscopically (nodes attached to and removed with the primary tumor may be positive) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localized tumor with incomplete gross excision; representative ipsilateral non‐adherent lymph nodes negative for tumor microscopically </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2B</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localized tumor with or without complete gross excision, with ipsilateral non‐adherent lymph nodes positive for tumor. Enlarged contralateral lymph nodes must be negative microscopically </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unresectable unilateral tumor infiltrating across the midline,<sup>1</sup> with or without regional lymph node involvement; or localized unilateral tumor with contralateral regional lymph node involvement; or midline tumor with bilateral extension by infiltration (unresectable) or by lymph node involvement </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin, and/or other organs (except as defined for stage 4S) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4S</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localized primary tumor (as defined for stages 1, 2A, or 2B), with dissemination limited to skin, liver, and/or bone marrow<sup>2</sup> (limited to infants &lt; 1 year of age) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>Reference: <a href="./references#CD010774-bbs2-0029" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a> </p> <p>Note: Multifocal primary tumors (e.g. bilateral adrenal primary tumors) should be staged according to the greatest extent of disease, as defined above, and followed by a subscript letter M (e.g. 3<sub>M</sub>).<br/> <sup>1</sup>The midline is defined as the vertebral column. Tumors originating on one side and crossing the midline must infiltrate to or beyond the opposite side of the vertebral column.<br/> <sup>2</sup>Marrow involvement in stage 4S should be minimal (i.e. &lt; 10% of total nucleated cells identified as malignant on bone marrow biopsy or on marrow aspirate). More extensive marrow involvement would be considered to be stage 4. An MIBG (meta‐iodobenzylguanidine) scan (if performed) should be negative in the marrow. </p> <p>Abbreviations: INSS: The International Neuroblastoma Staging System;</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">The International Neuroblastoma Staging System (INSS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010774-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Response to treatment</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Response</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Primary tumor</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Metastatic sites</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No tumor</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No tumor; catecholamines normal</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very good partial response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased by 90% to 99%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No tumor; catecholamines normal; residual <sup>99</sup>Tc bone changes allowed </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partial response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased by more than 50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All measurable sites decreased by greater than 50%. Bones and bone marrow: number of positive bone sites decreased by greater than 50%; no more than one positive bone marrow site allowed </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal response</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No new lesions; more than 50% reduction in any measurable lesion (primary or metastases) with less than 50% reduction in any other; less than 25% increase in any existing lesion </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No new lesions; less than 50% reduction but less than 25% increase in any existing lesion </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progressive disease</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Any new lesion; greater than 25% increase in any measurable lesion; previous negative marrow positive for tumor </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Reference: <a href="./references#CD010774-bbs2-0029" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Response to treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/full#CD010774-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010774-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Rapid COJEC versus standard induction</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.71, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Early toxicities <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Febrile neutropenia (two or more episodes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.10, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Proven fungal infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [0.23, 27.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Number of patients with septicemia (one or more episodes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.14, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Grade 3 or 4 gastrointestinal toxic effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.96, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Renal toxicity, GFR &lt; 80 ml/(min*1.73m*m)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [1.39, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Grade 3 or 4 neurological toxic effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [0.63, 14.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Ototoxicity (Brock 2 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.27, 4.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.33, 4.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.63, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Event‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Late non‐hematological toxicities <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.71, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Renal toxicity, GFR &lt; 80 ml/(min*1.73m*m)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.09, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Hearing loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.73, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Endocrine complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.18, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Neurocognitive complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.09, 0.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Rapid COJEC versus standard induction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010774.pub2/references#CD010774-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010774.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010774-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010774-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010774-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010774\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010774\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010774\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010774\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010774\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010774.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010774.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010774.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010774.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010774.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724599032"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010774.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724599035"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010774.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e66c27e37f44a',t:'MTc0MDcyNDU5OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 